Key result
In older adults with MDD, acute treatment with SNRIs, but not SSRIs, was associated with a greater number of overall adverse events versus placebo.
Why the study?
The adverse effects of pharmacologic antidepressants for treating major depressive disorder in adults aged 65 years or older needed to be systematically assessed.
Do pharmacologic antidepressants increase adverse events in adults 65 years of age or older with major depressive disorder?
Meta-Analysis
Do pharmacologic antidepressants increase adverse events in adults 65 years of age or older with major depressive disorder?
In older adults with MDD, SNRIs are associated with more overall adverse events than placebo during acute treatment, and duloxetine increases the risk of falls, highlighting the need for careful antidepressant selection.
Answers are grounded in this paper and cite their sources.
SNRIs warrant greater caution than SSRIs for tolerability in older adults with MDD; confirms differential adverse-event profiles in geriatric depression.
OBJECTIVES: To assess adverse effects of pharmacologic antidepressants for treatment of major depressive disorder (MDD) in adults 65 years of age or older. DESIGN: Systematic review and meta-analysis. SETTING: Specialist or generalist outpatient setting, rehabilitation facility, and nursing facilities. PARTICIPANTS: Persons 65 years and older with MDD. INTERVENTION: Selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), bupropion, mirtazapine, trazodone, vilazodone, or vortioxetine compared with another antidepressant, placebo, or nonpharmacologic therapy. MEASUREMENTS: Adverse events, arrhythmias, cognitive impairment, falls, fractures, hospitalization, mortality, QTc prolongation, serious adverse events, and withdrawals due to adverse events. RESULTS: Nineteen randomized controlled trials and two observational studies were included. Most studies evaluated treatment of the acute phase (<12 wk) of MDD of moderate severity. SSRIs led to a statistically similar frequency of overall adverse events vs placebo (moderate strength of evidence [SOE]), but SNRIs caused more overall adverse events vs placebo (high SOE) during the acute treatment phase. Both SSRIs and SNRIs led to more study withdrawals due to adverse events vs placebo (SSRIs low SOE; SNRIs moderate SOE). Duloxetine led to a more falls vs placebo (moderate SOE) during 24 weeks of acute and continuation treatment of MDD. CONCLUSION: In patients 65 years of age or older with MDD, treatment of the acute phase of MDD with SNRIs, but not SSRIs, was associated with a statistically greater number of overall adverse events vs placebo. SSRIs and SNRIs led to a greater number of study withdrawals due to adverse events vs placebo. Duloxetine increased the risk of falls that as an outcome was underreported in the literature. Few studies examined head-to-head comparisons, most trials were not powered to evaluate adverse events, and results of observational studies may be confounded. Comparative long-term studies reporting specific adverse events are needed to inform clinical decision making regarding choice of antidepressants in this population. J Am Geriatr Soc 67:1571-1581, 2019.
No takes yet. Share an insight, caveat, or question.
Sobieraj et al. (2019) conducted a meta-analysis in Major depressive disorder (MDD). Pharmacologic antidepressants (SSRIs, SNRIs, bupropion, mirtazapine, trazodone, vilazodone, or vortioxetine) vs. Another antidepressant, placebo, or nonpharmacologic therapy was evaluated on Overall adverse events. In older adults with MDD, acute treatment with SNRIs, but not SSRIs, was associated with a greater number of overall adverse events versus placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: